These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10082034)

  • 21. Biomarkers for Hepatocellular Carcinoma (HCC): An Update.
    Li D; Satomura S
    Adv Exp Med Biol; 2015; 867():179-93. PubMed ID: 26530367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.
    Mantovani G
    Ann Oncol; 2008 Jul; 19(7):1355. PubMed ID: 18522933
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma.
    Yin L; He N; Chen C; Zhang N; Lin Y; Xia Q
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1908-1916. PubMed ID: 31072138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spontaneous regression of hepatocellular carcinoma.
    Kondo S; Okusaka T; Ueno H; Ikeda M; Morizane C
    Int J Clin Oncol; 2006 Oct; 11(5):407-11. PubMed ID: 17058140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P53 in sera for the early detection of hepatocellular carcinoma.
    Sakamoto M
    J Gastroenterol; 2001 Dec; 36(12):865-6. PubMed ID: 11777218
    [No Abstract]   [Full Text] [Related]  

  • 26. Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?
    Wang YY; Zhong JH; Lu Z; Qin HG; Li LQ
    Tumour Biol; 2015 Nov; 36(11):8273-4. PubMed ID: 26515333
    [No Abstract]   [Full Text] [Related]  

  • 27. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.
    Chen LT; Shiah HS; Chao Y; Chang JY; Cheng LT; Whang-Peng J
    J Clin Oncol; 2009 Dec; 27(36):e271; author reply e272. PubMed ID: 19917866
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum glycan as a prognostic marker in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Miyahara K; Nouso K; Miyake Y; Nakamura S; Obi S; Amano M; Hirose K; Nishimura S; Yamamoto K
    Hepatology; 2014 Jan; 59(1):355-6. PubMed ID: 23729393
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma.
    Hwang HM; Heo CK; Lee HJ; Kwak SS; Lim WH; Yoo JS; Yu DY; Lim KJ; Kim JY; Cho EW
    J Transl Med; 2018 Jun; 16(1):177. PubMed ID: 29954402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
    Wen Y; Han J; Chen J; Dong J; Xia Y; Liu J; Jiang Y; Dai J; Lu J; Jin G; Han J; Wei Q; Shen H; Sun B; Hu Z
    Int J Cancer; 2015 Oct; 137(7):1679-90. PubMed ID: 25845839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
    World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
    Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
    Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma level of vitamin K-dependent clotting factors as marker for hepatocellular carcinoma.
    Denninger MH; Degos F; Poilane I; Degott C; Benhamou JP; Guillin MC
    J Hepatol; 1991 Mar; 12(2):261-2. PubMed ID: 1646836
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection.
    Waidely E; Al-Yuobi AR; Bashammakh AS; El-Shahawi MS; Leblanc RM
    Analyst; 2016 Jan; 141(1):36-44. PubMed ID: 26606739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
    Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.
    Zhang C; Xia R; Zhang B; Wang H
    BMC Cancer; 2018 Nov; 18(1):1110. PubMed ID: 30424721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma.
    Lu Y; Li N; Gao L; Xu YJ; Huang C; Yu K; Ling Q; Cheng Q; Chen S; Zhu M; Fang J; Chen M; Ong CN
    Cancer Res; 2016 May; 76(10):2912-20. PubMed ID: 26976432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FAT 10 protein as a potential serological marker in the diagnosis of hepatocellullar carcinoma.
    Zhang SY; Cao N; Chen MK; Zhang LD; Bai YQ; Ding SZ; Yang YX
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):711-714. PubMed ID: 28754570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.